201 related articles for article (PubMed ID: 25142323)
1. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics.
Li CH; Stratford RE; Velez de Mendizabal N; Cremers TI; Pollock BG; Mulsant BH; Remington G; Bies RR
J Transl Med; 2014 Aug; 12():203. PubMed ID: 25142323
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
3. Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics.
Albitar O; Harun SN; Sheikh Ghadzi SM
CNS Drugs; 2024 Jul; 38(7):571-581. PubMed ID: 38836990
[TBL] [Abstract][Full Text] [Related]
4. The Drug-Drug Effects of Rhein on the Pharmacokinetics and Pharmacodynamics of Clozapine in Rat Brain Extracellular Fluid by In Vivo Microdialysis.
Hou ML; Lin CH; Lin LC; Tsai TH
J Pharmacol Exp Ther; 2015 Oct; 355(1):125-34. PubMed ID: 26220937
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.
Li LJ; Shang DW; Li WB; Guo W; Wang XP; Ren YP; Li AN; Fu PX; Ji SM; Lu W; Wang CY
Acta Pharmacol Sin; 2012 Nov; 33(11):1409-16. PubMed ID: 22820910
[TBL] [Abstract][Full Text] [Related]
6. Effect of hypertriglyceridemia on the pharmacokinetics and blood-brain barrier penetration of clozapine and norclozapine following administration to rats.
Gershkovich P; Sivak O; Sharma A; Barr AM; Procyshyn R; Wasan KM
Eur Neuropsychopharmacol; 2010 Aug; 20(8):545-52. PubMed ID: 20163937
[TBL] [Abstract][Full Text] [Related]
7. Effect of post-mortem changes on peripheral and central whole blood and tissue clozapine and norclozapine concentrations in the domestic pig (Sus scrofa).
Flanagan RJ; Amin A; Seinen W
Forensic Sci Int; 2003 Mar; 132(1):9-17. PubMed ID: 12689746
[TBL] [Abstract][Full Text] [Related]
8. Making sense of norclozapine levels: 3 clinical axioms.
Meyer JM
Schizophr Res; 2024 Jun; 268():289-292. PubMed ID: 37945386
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid.
Li Z; Lee SH; Jeong HJ; Kang HE
Xenobiotica; 2021 Mar; 51(3):324-334. PubMed ID: 33185134
[TBL] [Abstract][Full Text] [Related]
10. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study.
Ng W; Uchida H; Ismail Z; Mamo DC; Rajji TK; Remington G; Sproule B; Pollock BG; Mulsant BH; Bies RR
Ther Drug Monit; 2009 Jun; 31(3):360-6. PubMed ID: 19349931
[TBL] [Abstract][Full Text] [Related]
11. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics.
Lane HY; Chang YC; Chang WH; Lin SK; Tseng YT; Jann MW
J Clin Psychiatry; 1999 Jan; 60(1):36-40. PubMed ID: 10074876
[TBL] [Abstract][Full Text] [Related]
12. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
13. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia.
Ismail Z; Wessels AM; Uchida H; Ng W; Mamo DC; Rajji TK; Pollock BG; Mulsant BH; Bies RR
Am J Geriatr Psychiatry; 2012 Jan; 20(1):53-60. PubMed ID: 21422906
[TBL] [Abstract][Full Text] [Related]
14. Features and toxicokinetics of clozapine in overdose.
Reith D; Monteleone JP; Whyte IM; Ebelling W; Holford NH; Carter GL
Ther Drug Monit; 1998 Feb; 20(1):92-7. PubMed ID: 9485562
[TBL] [Abstract][Full Text] [Related]
15. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
16. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
17. A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment.
Guitton C; Kinowski JM; Gomeni R; Bressolle F
Clin Drug Investig; 1998; 16(1):35-43. PubMed ID: 18370516
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.
Hermida J; Paz E; Tutor JC
Ther Drug Monit; 2008 Feb; 30(1):41-5. PubMed ID: 18223461
[TBL] [Abstract][Full Text] [Related]
19. Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients.
Menkes DB; Glue P; Gale C; Lam F; Hung CT; Hung N
EBioMedicine; 2018 Jan; 27():134-137. PubMed ID: 29254680
[TBL] [Abstract][Full Text] [Related]
20. Determination of clozapine and its metabolite, norclozapine in various biological matrices using high-performance liquid chromatography.
Rosland M; Szeto P; Procyshyn R; Barr AM; Wasan KM
Drug Dev Ind Pharm; 2007 Oct; 33(10):1158-66. PubMed ID: 17963117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
